title: Anaphylaxis and serum sickness in patients receiving omalizumab: reviewing the data in light of clinical experience.
authors.affiliation: Ottawa Allergy Research Corporation, Ottawa, Ontario, Canada. Electronic address: rharrison@redmapletrials.com.
authors.forename: Rachel G
authors.initials: RG
authors.lastname: Harrison
authors.affiliation: Ottawa Allergy Research Corporation, Ottawa, Ontario, Canada.
authors.forename: Megan
authors.initials: M
authors.lastname: MacRae
authors.affiliation: University of Ottawa Medical School, Ottawa, Ontario, Canada.
authors.forename: Jacob
authors.initials: J
authors.lastname: Karsh
authors.affiliation: Ottawa Allergy Research Corporation, Ottawa, Ontario, Canada.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Santucci
authors.affiliation: Ottawa Allergy Research Corporation, Ottawa, Ontario, Canada; University of Ottawa Medical School, Ottawa, Ontario, Canada.
authors.forename: William H
authors.initials: WH
authors.lastname: Yang
mesh_terms: D000707:Anaphylaxis / Q000139:chemically induced* / Q000453:epidemiology; D000888:Antibodies, Anti-Idiotypic / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D002170:Canada; D004342:Drug Hypersensitivity / Q000453:epidemiology / Q000209:etiology*; D004348:Drug Labeling; D006801:Humans; D000069444:Omalizumab; D015995:Prevalence; D011358:Product Surveillance, Postmarketing; D012713:Serum Sickness / Q000453:epidemiology / Q000209:etiology*; D014481:United States / Q000453:epidemiology
chemical_list: D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab